You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameUdenafil
Accession NumberDB06267
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Structure
Thumb
Synonyms
DA-8159
Udenafil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ZydenaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIL5IB4XLY36
CAS number268203-93-6
WeightAverage: 516.656
Monoisotopic: 516.25187436
Chemical FormulaC25H36N6O4S
InChI KeyInChIKey=IYFNEFQTYQPVOC-UHFFFAOYSA-N
InChI
InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
IUPAC Name
3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide
SMILES
CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Pyrazolopyrimidine
  • Phenol ether
  • Pyrimidone
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Pyrazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in erectile dysfunction and hypertension.
PharmacodynamicsUdenafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor.
Mechanism of actionUdenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by udenafil enhances erectile function by increasing the amount of cGMP.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Metabolized by CYP3A4 and CYP3A5.

SubstrateEnzymesProduct
Udenafil
N-desalkyludenafilDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.5
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8093
P-glycoprotein inhibitor IInhibitor0.6138
P-glycoprotein inhibitor IIInhibitor0.658
Renal organic cation transporterNon-inhibitor0.784
CYP450 2C9 substrateNon-substrate0.6694
CYP450 2D6 substrateSubstrate0.6391
CYP450 3A4 substrateSubstrate0.721
CYP450 1A2 substrateNon-inhibitor0.8355
CYP450 2C9 inhibitorInhibitor0.5391
CYP450 2D6 inhibitorNon-inhibitor0.8885
CYP450 2C19 inhibitorNon-inhibitor0.8588
CYP450 3A4 inhibitorInhibitor0.8863
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5793
Ames testNon AMES toxic0.5747
CarcinogenicityNon-carcinogens0.5502
BiodegradationNot ready biodegradable0.8961
Rat acute toxicity2.6102 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8455
hERG inhibition (predictor II)Inhibitor0.805
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0798 mg/mLALOGPS
logP3.2ALOGPS
logP1.66ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)7.21ChemAxon
pKa (Strongest Basic)8.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area117.92 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity153.11 m3·mol-1ChemAxon
Polarizability56.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Chan-Ho Lee, Chang-Yong Shin, Seul-Min Choi, Kyung-Koo Kang, Dong-Seong Kim, Byoung-Ok Ahn, Moo-Hi Yoo, “ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME.” U.S. Patent US20110306762, issued December 15, 2011.

US20110306762
General References
  1. Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. 2007 Sep;30(9):1168-73. [PubMed:17958337 ]
  2. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836 ]
External Links
ATC CodesG04BE11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololUdenafil may increase the antihypertensive activities of Acebutolol.
AlfuzosinUdenafil may increase the hypotensive activities of Alfuzosin.
AliskirenUdenafil may increase the antihypertensive activities of Aliskiren.
AlprenololUdenafil may increase the antihypertensive activities of Alprenolol.
AlprostadilThe risk or severity of adverse effects can be increased when Udenafil is combined with Alprostadil.
AmbrisentanUdenafil may increase the antihypertensive activities of Ambrisentan.
AmiodaroneThe metabolism of Udenafil can be decreased when combined with Amiodarone.
AmlodipineUdenafil may increase the antihypertensive activities of Amlodipine.
Amyl NitriteUdenafil may increase the vasodilatory activities of Amyl Nitrite.
AprepitantThe serum concentration of Udenafil can be increased when it is combined with Aprepitant.
AtazanavirThe metabolism of Udenafil can be decreased when combined with Atazanavir.
AtenololUdenafil may increase the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Udenafil can be decreased when combined with Atomoxetine.
BenazeprilUdenafil may increase the antihypertensive activities of Benazepril.
BendroflumethiazideUdenafil may increase the antihypertensive activities of Bendroflumethiazide.
BepridilUdenafil may increase the antihypertensive activities of Bepridil.
BetaxololUdenafil may increase the antihypertensive activities of Betaxolol.
BethanidineUdenafil may increase the antihypertensive activities of Bethanidine.
BexaroteneThe serum concentration of Udenafil can be decreased when it is combined with Bexarotene.
BimatoprostUdenafil may increase the antihypertensive activities of Bimatoprost.
BisoprololUdenafil may increase the antihypertensive activities of Bisoprolol.
BoceprevirThe metabolism of Udenafil can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Udenafil can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Udenafil can be decreased when it is combined with Bosentan.
BosentanUdenafil may increase the antihypertensive activities of Bosentan.
BretyliumUdenafil may increase the antihypertensive activities of Bretylium.
BrimonidineUdenafil may increase the antihypertensive activities of Brimonidine.
BupranololUdenafil may increase the antihypertensive activities of Bupranolol.
CandesartanUdenafil may increase the antihypertensive activities of Candesartan.
CandoxatrilUdenafil may increase the antihypertensive activities of Candoxatril.
CaptoprilUdenafil may increase the antihypertensive activities of Captopril.
CarbamazepineThe metabolism of Udenafil can be increased when combined with Carbamazepine.
CarteololUdenafil may increase the antihypertensive activities of Carteolol.
CarvedilolUdenafil may increase the antihypertensive activities of Carvedilol.
CeliprololUdenafil may increase the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Udenafil can be increased when it is combined with Ceritinib.
ChlorothiazideUdenafil may increase the antihypertensive activities of Chlorothiazide.
ChlorthalidoneUdenafil may increase the antihypertensive activities of Chlorthalidone.
CilazaprilUdenafil may increase the antihypertensive activities of Cilazapril.
ClarithromycinThe metabolism of Udenafil can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Udenafil can be decreased when combined with Clemastine.
ClonidineUdenafil may increase the antihypertensive activities of Clonidine.
ClotrimazoleThe metabolism of Udenafil can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Udenafil can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Udenafil can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Udenafil can be decreased when combined with Crizotinib.
CryptenamineUdenafil may increase the antihypertensive activities of Cryptenamine.
CyclosporineThe metabolism of Udenafil can be decreased when combined with Cyclosporine.
CyclothiazideUdenafil may increase the antihypertensive activities of Cyclothiazide.
DabrafenibThe serum concentration of Udenafil can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Udenafil.
DarunavirThe metabolism of Udenafil can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Udenafil can be increased when it is combined with Dasatinib.
DebrisoquinUdenafil may increase the antihypertensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Udenafil can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Udenafil can be decreased when combined with Delavirdine.
DeserpidineUdenafil may increase the antihypertensive activities of Deserpidine.
DexamethasoneThe serum concentration of Udenafil can be decreased when it is combined with Dexamethasone.
DiazoxideUdenafil may increase the antihypertensive activities of Diazoxide.
DihydroergotamineThe metabolism of Udenafil can be decreased when combined with Dihydroergotamine.
DiltiazemUdenafil may increase the antihypertensive activities of Diltiazem.
DiltiazemThe metabolism of Udenafil can be decreased when combined with Diltiazem.
DorzolamideUdenafil may increase the antihypertensive activities of Dorzolamide.
DoxazosinUdenafil may increase the antihypertensive activities of Doxazosin.
DoxycyclineThe metabolism of Udenafil can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Udenafil can be decreased when combined with Dronedarone.
EfavirenzThe serum concentration of Udenafil can be decreased when it is combined with Efavirenz.
EfonidipineUdenafil may increase the antihypertensive activities of Efonidipine.
EnalaprilUdenafil may increase the antihypertensive activities of Enalapril.
EnalaprilatUdenafil may increase the antihypertensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Udenafil can be decreased when it is combined with Enzalutamide.
EpoprostenolUdenafil may increase the antihypertensive activities of Epoprostenol.
EprosartanUdenafil may increase the antihypertensive activities of Eprosartan.
Erythrityl TetranitrateUdenafil may increase the vasodilatory activities of Erythrityl Tetranitrate.
ErythromycinThe metabolism of Udenafil can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Udenafil can be decreased when it is combined with Eslicarbazepine acetate.
EthanolEthanol may increase the hypotensive activities of Udenafil.
EtravirineThe serum concentration of Udenafil can be decreased when it is combined with Etravirine.
FelodipineUdenafil may increase the antihypertensive activities of Felodipine.
FenoldopamUdenafil may increase the antihypertensive activities of Fenoldopam.
FluconazoleThe metabolism of Udenafil can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Udenafil can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Udenafil can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Udenafil can be increased when it is combined with Fosaprepitant.
FosinoprilUdenafil may increase the antihypertensive activities of Fosinopril.
FosphenytoinThe metabolism of Udenafil can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Udenafil can be increased when it is combined with Fusidic Acid.
GuanabenzUdenafil may increase the antihypertensive activities of Guanabenz.
GuanadrelUdenafil may increase the antihypertensive activities of Guanadrel.
GuanethidineUdenafil may increase the antihypertensive activities of Guanethidine.
GuanfacineUdenafil may increase the antihypertensive activities of Guanfacine.
HexamethoniumUdenafil may increase the antihypertensive activities of Hexamethonium.
HydralazineUdenafil may increase the antihypertensive activities of Hydralazine.
HydrochlorothiazideUdenafil may increase the antihypertensive activities of Hydrochlorothiazide.
HydroflumethiazideUdenafil may increase the antihypertensive activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Udenafil can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Udenafil can be decreased when combined with Imatinib.
IndapamideUdenafil may increase the antihypertensive activities of Indapamide.
IndenololUdenafil may increase the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Udenafil can be decreased when combined with Indinavir.
IndoraminUdenafil may increase the antihypertensive activities of Indoramin.
IrbesartanUdenafil may increase the antihypertensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Udenafil can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateUdenafil may increase the vasodilatory activities of Isosorbide Dinitrate.
Isosorbide MononitrateUdenafil may increase the vasodilatory activities of Isosorbide Mononitrate.
IsradipineUdenafil may increase the antihypertensive activities of Isradipine.
IsradipineThe metabolism of Udenafil can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Udenafil can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Udenafil can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Udenafil can be decreased when combined with Ketoconazole.
LabetalolUdenafil may increase the antihypertensive activities of Labetalol.
LacidipineUdenafil may increase the antihypertensive activities of Lacidipine.
LatanoprostUdenafil may increase the antihypertensive activities of Latanoprost.
LercanidipineUdenafil may increase the antihypertensive activities of Lercanidipine.
LisinoprilUdenafil may increase the antihypertensive activities of Lisinopril.
LofexidineUdenafil may increase the antihypertensive activities of Lofexidine.
LopinavirThe metabolism of Udenafil can be decreased when combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Udenafil.
LosartanUdenafil may increase the antihypertensive activities of Losartan.
LovastatinThe metabolism of Udenafil can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Udenafil can be increased when it is combined with Luliconazole.
MacitentanUdenafil may increase the antihypertensive activities of Macitentan.
ManidipineUdenafil may increase the antihypertensive activities of Manidipine.
MecamylamineUdenafil may increase the antihypertensive activities of Mecamylamine.
MethyldopaUdenafil may increase the antihypertensive activities of Methyldopa.
MetipranololUdenafil may increase the antihypertensive activities of Metipranolol.
MetolazoneUdenafil may increase the antihypertensive activities of Metolazone.
MetoprololUdenafil may increase the antihypertensive activities of Metoprolol.
MibefradilUdenafil may increase the antihypertensive activities of Mibefradil.
MifepristoneThe metabolism of Udenafil can be decreased when combined with Mifepristone.
MinoxidilUdenafil may increase the antihypertensive activities of Minoxidil.
MitotaneThe serum concentration of Udenafil can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Udenafil can be decreased when it is combined with Modafinil.
MoexiprilUdenafil may increase the antihypertensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Udenafil.
MoxonidineUdenafil may increase the antihypertensive activities of Moxonidine.
NadololUdenafil may increase the antihypertensive activities of Nadolol.
NafcillinThe serum concentration of Udenafil can be decreased when it is combined with Nafcillin.
NebivololUdenafil may increase the antihypertensive activities of Nebivolol.
NefazodoneThe metabolism of Udenafil can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Udenafil can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Udenafil can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Udenafil can be decreased when combined with Nevirapine.
NicardipineUdenafil may increase the antihypertensive activities of Nicardipine.
NicorandilUdenafil may increase the antihypertensive activities of Nicorandil.
NiguldipineUdenafil may increase the antihypertensive activities of Niguldipine.
NilotinibThe metabolism of Udenafil can be decreased when combined with Nilotinib.
NilvadipineUdenafil may increase the antihypertensive activities of Nilvadipine.
NimodipineUdenafil may increase the antihypertensive activities of Nimodipine.
NisoldipineUdenafil may increase the antihypertensive activities of Nisoldipine.
NitrendipineUdenafil may increase the antihypertensive activities of Nitrendipine.
NitroglycerinUdenafil may increase the vasodilatory activities of Nitroglycerin.
NitroprussideUdenafil may increase the antihypertensive activities of Nitroprusside.
OlaparibThe metabolism of Udenafil can be decreased when combined with Olaparib.
OlmesartanUdenafil may increase the antihypertensive activities of Olmesartan.
OmapatrilatUdenafil may increase the antihypertensive activities of Omapatrilat.
OsimertinibThe serum concentration of Udenafil can be increased when it is combined with Osimertinib.
OxprenololUdenafil may increase the antihypertensive activities of Oxprenolol.
PalbociclibThe serum concentration of Udenafil can be increased when it is combined with Palbociclib.
PargylineUdenafil may increase the antihypertensive activities of Pargyline.
PenbutololUdenafil may increase the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Udenafil can be increased when combined with Pentobarbital.
PentoliniumUdenafil may increase the antihypertensive activities of Pentolinium.
PerindoprilUdenafil may increase the antihypertensive activities of Perindopril.
PhenobarbitalThe metabolism of Udenafil can be increased when combined with Phenobarbital.
PhenoxybenzamineUdenafil may increase the antihypertensive activities of Phenoxybenzamine.
PhentolamineUdenafil may increase the antihypertensive activities of Phentolamine.
PhenytoinThe metabolism of Udenafil can be increased when combined with Phenytoin.
PinacidilUdenafil may increase the antihypertensive activities of Pinacidil.
PindololUdenafil may increase the antihypertensive activities of Pindolol.
PolythiazideUdenafil may increase the antihypertensive activities of Polythiazide.
PosaconazoleThe metabolism of Udenafil can be decreased when combined with Posaconazole.
PrazosinUdenafil may increase the antihypertensive activities of Prazosin.
PrimidoneThe metabolism of Udenafil can be increased when combined with Primidone.
PropranololUdenafil may increase the antihypertensive activities of Propranolol.
QuinaprilUdenafil may increase the antihypertensive activities of Quinapril.
RamiprilUdenafil may increase the antihypertensive activities of Ramipril.
RanolazineThe metabolism of Udenafil can be decreased when combined with Ranolazine.
RemikirenUdenafil may increase the antihypertensive activities of Remikiren.
RescinnamineUdenafil may increase the antihypertensive activities of Rescinnamine.
ReserpineUdenafil may increase the antihypertensive activities of Reserpine.
RifabutinThe metabolism of Udenafil can be increased when combined with Rifabutin.
RifampicinThe metabolism of Udenafil can be increased when combined with Rifampicin.
RifapentineThe metabolism of Udenafil can be increased when combined with Rifapentine.
RiociguatUdenafil may increase the hypotensive activities of Riociguat.
RitonavirThe metabolism of Udenafil can be decreased when combined with Ritonavir.
SaprisartanUdenafil may increase the antihypertensive activities of Saprisartan.
SapropterinSapropterin may increase the hypotensive activities of Udenafil.
SaquinavirThe metabolism of Udenafil can be decreased when combined with Saquinavir.
SelexipagUdenafil may increase the antihypertensive activities of Selexipag.
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Udenafil.
SilodosinUdenafil may increase the hypotensive activities of Silodosin.
SiltuximabThe serum concentration of Udenafil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Udenafil can be increased when it is combined with Simeprevir.
SitaxentanUdenafil may increase the antihypertensive activities of Sitaxentan.
SpiraprilUdenafil may increase the antihypertensive activities of Spirapril.
St. John's WortThe serum concentration of Udenafil can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Udenafil can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Udenafil can be decreased when combined with Sulfisoxazole.
TadalafilThe risk or severity of adverse effects can be increased when Tadalafil is combined with Udenafil.
TamsulosinUdenafil may increase the hypotensive activities of Tamsulosin.
TelaprevirThe metabolism of Udenafil can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Udenafil can be decreased when combined with Telithromycin.
TelmisartanUdenafil may increase the antihypertensive activities of Telmisartan.
TemocaprilUdenafil may increase the antihypertensive activities of Temocapril.
TerazosinUdenafil may increase the hypotensive activities of Terazosin.
TerlipressinUdenafil may increase the antihypertensive activities of Terlipressin.
TiboloneUdenafil may increase the antihypertensive activities of Tibolone.
TiclopidineThe metabolism of Udenafil can be decreased when combined with Ticlopidine.
TicrynafenUdenafil may increase the antihypertensive activities of Ticrynafen.
TimololUdenafil may increase the antihypertensive activities of Timolol.
TocilizumabThe serum concentration of Udenafil can be decreased when it is combined with Tocilizumab.
TolazolineUdenafil may increase the antihypertensive activities of Tolazoline.
TorasemideUdenafil may increase the antihypertensive activities of Torasemide.
TrandolaprilUdenafil may increase the antihypertensive activities of Trandolapril.
TravoprostUdenafil may increase the antihypertensive activities of Travoprost.
TreprostinilUdenafil may increase the antihypertensive activities of Treprostinil.
TrichlormethiazideUdenafil may increase the antihypertensive activities of Trichlormethiazide.
TrimazosinUdenafil may increase the antihypertensive activities of Trimazosin.
TrimethaphanUdenafil may increase the antihypertensive activities of Trimethaphan.
UnoprostoneUdenafil may increase the antihypertensive activities of Unoprostone.
ValsartanUdenafil may increase the antihypertensive activities of Valsartan.
VardenafilThe risk or severity of adverse effects can be increased when Vardenafil is combined with Udenafil.
VenlafaxineThe metabolism of Udenafil can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Udenafil can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Udenafil can be decreased when combined with Voriconazole.
XylometazolineUdenafil may increase the antihypertensive activities of Xylometazoline.
ZiprasidoneThe metabolism of Udenafil can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Gur S, Sikka SC, Hellstrom WJ: Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. doi: 10.1517/13543784.17.6.855 . [PubMed:18491987 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO: Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009 Jul;11(4):435-42. doi: 10.1038/aja.2009.27. Epub 2009 May 25. [PubMed:19465935 ]
  4. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK: Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5. [PubMed:21054754 ]
  5. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C: PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des. 2009;15(30):3464-75. [PubMed:19860692 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, Lee HS: Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica. 2004 Nov-Dec;34(11-12):973-82. [PubMed:15801542 ]
  2. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:20 / Updated on August 17, 2016 12:24